Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.67 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.67 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.67 |
| ▸ | MET | P08581 | 1/20 | 0.63 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.56 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2286610 | 0.90 | MAPK14 (0.82) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL2287532 | 0.87 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL27784852 | 0.86 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL2289030 | 0.85 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL2891559 | 0.84 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL2888593 | 0.84 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL2886849 | 0.83 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL2889213 | 0.82 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL2787040 | 0.82 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL6646016 | 0.81 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103842362-A | Compositions and methods for treating Alzheimer's disease | EIP PHARMA LLC | 2014-06-04 | — | — | CN | claimed |
| EP-2707369-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Eip Pharma, LLC (US) | 2014-03-19 | — | — | EP | claimed |
| EP-2428210-B1 | P38 MAPK INHIBITORS FOR USE IN TREATING OCULAR HYPERTENSION | NOVARTIS AG (CH) | 2013-07-10 | — | — | EP | claimed |
| WO-2012154814-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | WO | claimed |
| US-7662389-B2 | Gene expression inhibition; p38 map kinase inhibitors | ALCON, INC. (CH) | 2010-02-16 | — | — | US | claimed |
| EP-1025102-B1 | BICYCLIC KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2004-05-19 | — | — | EP | claimed |
| CN-1279682-A | bicyclic kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2001-01-10 | — | — | CN | claimed |
| US-20250302883-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2025-10-02 | — | — | US | disclosed |
| US-20230057984-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-3081568-B1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA LLC (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3081568-B1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA LLC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10441577-B2 | Medicament for treatment of liver cancer | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG (DE) | 2019-10-15 | — | — | US | disclosed |
| EP-3081568-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Eip Pharma, LLC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020013354-A1 | p38 map kinase inhibitors | CHENG SOAN (US) | 2002-01-31 | — | — | US | disclosed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| CN-1279682-A | bicyclic kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2001-01-10 | — | — | CN | disclosed |
| EP-1025102-A1 | BICYCLIC KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020624-A1 | BICYCLIC KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013354-A1 | p38 map kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885MAPK13 33/4885MAPK12 35/4885 |
| US-10441577-B2 | Medicament for treatment of liver cancer | PYGL, PFKL, GLS2 | MAPK14 523/4885MAPK13 685/4885MAPK12 538/4885 |
| US-20010044538-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885MAPK13 33/4885MAPK12 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.